Total net sales increased by $102.4 million, or 28.4%, to $463.062 million for the year ended December 31, 2025, compared to the prior year. The Stokers products segment saw net sales surge by $116.3 million, or 69.1%, driven predominantly by $107.7 million in modern oral product growth. Gross profit rose by $62.7 million, or 31.1%, reaching $264.314 million, with the gross profit margin improving to 57.1% from 55.9% in 2024, mainly due to higher margin contributions from modern oral products and MST. Net income attributable to Turning Point Brands, Inc. increased by 22.9% to $58.165 million in 2025 from $47.326 million in 2024. Adjusted EBITDA grew to $119.522 million in 2025, up from $104.459 million in 2024. Cash on hand significantly increased to $222.8 million as of December 31, 2025, compared to $46.2 million at the end of 2024. The company successfully remediated a previously identified material weakness in internal control over financial reporting related to ineffective information technology general controls as of December 31, 2025. The CDS reportable segment was classified as discontinued operations and divested on January 2, 2025, resulting in no loss from discontinued operations in 2025 compared to a $7.5 million loss in 2024. Issued $300.0 million of 7.625% Senior Secured Notes due 2032 in February 2025, using proceeds to redeem the existing 5.625% Senior Secured Notes due 2026.